Literature DB >> 26220173

Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.

Francesca Lavatelli1, Esther Imperlini1, Stefania Orrù1, Paola Rognoni1, Daniela Sarnataro1, Giuseppina Palladini1, Giuseppe Malpasso1, Maria Eugenia Soriano1, Andrea Di Fonzo1, Veronica Valentini1, Massimiliano Gnecchi1, Stefano Perlini1, Francesco Salvatore2, Giampaolo Merlini2.   

Abstract

In immunoglobulin (Ig) light-chain (LC) (AL) amyloidosis, AL deposition translates into life-threatening cardiomyopathy. Clinical and experimental evidence indicates that soluble cardiotoxic LCs are themselves harmful for cells, by which they are internalized. Hypothesizing that interaction of soluble cardiotoxic LCs with cellular proteins contributes to damage, we characterized their interactome in cardiac cells. LCs were purified from patients with AL amyloidosis cardiomyopathy or multiple myeloma without amyloidosis (the nonamyloidogenic/noncardiotoxic LCs served as controls) and employed at concentrations in the range observed in AL patients' sera. A functional proteomic approach, based on direct and inverse coimmunoprecipitation and mass spectrometry, allowed identifying LC-protein complexes. Findings were validated by colocalization, fluorescence lifetime imaging microscopy (FLIM)-fluorescence resonance energy transfer (FRET), and ultrastructural studies, using human primary cardiac fibroblasts (hCFs) and stem cell-derived cardiomyocytes. Amyloidogenic cardiotoxic LCs interact in vitro with specific intracellular proteins involved in viability and metabolism. Imaging confirmed that, especially in hCFs, cardiotoxic LCs (not controls) colocalize with mitochondria and spatially associate with selected interactors: mitochondrial optic atrophy 1-like protein and peroxisomal acyl-coenzyme A oxidase 1 (FLIM-FRET efficiencies 11 and 6%, respectively). Cardiotoxic LC-treated hCFs display mitochondrial ultrastructural changes, supporting mitochondrial involvement. We show that cardiotoxic LCs establish nonphysiologic protein-protein contacts in human cardiac cells, offering new clues on the pathogenesis of AL cardiomyopathy. © FASEB.

Entities:  

Keywords:  functional proteomics; human cardiac cells; protein-misfolding diseases; protein–protein interaction; proteotoxicity

Mesh:

Substances:

Year:  2015        PMID: 26220173     DOI: 10.1096/fj.15-272179

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  21 in total

Review 1.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

2.  Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Authors:  Paolo Milani; Angela Dispenzieri; Christopher G Scott; Morie A Gertz; Stefano Perlini; Roberta Mussinelli; Martha Q Lacy; Francis K Buadi; Shaji Kumar; Mathew S Maurer; Giampaolo Merlini; Suzanne R Hayman; Nelson Leung; David Dingli; Kyle W Klarich; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Patricia A Pellikka; Yi L Hwa; Stephen R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Martha Grogan
Journal:  Circ Cardiovasc Imaging       Date:  2018-05       Impact factor: 7.792

Review 3.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.

Authors:  Luisa Diomede; Margherita Romeo; Paola Rognoni; Marten Beeg; Claudia Foray; Elena Ghibaudi; Giovanni Palladini; Robert A Cherny; Laura Verga; Gian Luca Capello; Vittorio Perfetti; Fabio Fiordaliso; Giampaolo Merlini; Mario Salmona
Journal:  Antioxid Redox Signal       Date:  2017-03-03       Impact factor: 8.401

Review 5.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

6.  Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration.

Authors:  Shikha Mishra; Shaurya Joshi; Jennifer E Ward; Eva P Buys; Deepak Mishra; Deepa Mishra; Isabel Morgado; Sudeshna Fisch; Francesca Lavatelli; Giampaolo Merlini; Sharmila Dorbala; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-15       Impact factor: 4.733

Review 7.  Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies.

Authors:  Maurizio Pieroni; Michele Ciabatti; Elisa Saletti; Valentina Tavanti; Pasquale Santangeli; Lucia Martinese; Francesco Liistro; Iacopo Olivotto; Leonardo Bolognese
Journal:  Curr Cardiol Rep       Date:  2022-09-02       Impact factor: 3.955

Review 8.  Immunoglobulin light chain amyloid aggregation.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Shawna A Cooper; Keely R Redhage; Michael R Bergman; Torri L Jordan; Khansaa Maar; Marina Ramirez-Alvarado
Journal:  Chem Commun (Camb)       Date:  2018-09-20       Impact factor: 6.222

Review 9.  Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy.

Authors:  Valerie Sapp; Mohit Jain; Ronglih Liao
Journal:  Physiology (Bethesda)       Date:  2016-07

Review 10.  Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Authors:  G Merlini; I Lousada; Y Ando; A Dispenzieri; M A Gertz; M Grogan; M S Maurer; V Sanchorawala; A Wechalekar; G Palladini; R L Comenzo
Journal:  Leukemia       Date:  2016-07-15       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.